Study #2016-0648
A Two-Part Phase 1/2 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy Subjects and in Subjects with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acu
MD Anderson Study Status
Not Accepting
Treatment Agent
Vodobatinib (K0706) capsules
Description
Phase 1/2 study to determine safety, tolerability, pharmacokinetics, and anti-leukemic activity of Vodobatinib (K0706) in treatment-refractory/intolerant CML
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C)
Study phase:
Physician name:
Yesid Alvarado
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.